Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease - Test2 - elhamkhani - TriplyDB

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

http://www.wikidata.org/entity/Q30581321

about

Developing stem cell therapies for juvenile and adult-onset Huntington's disease The choreography of neuroinflammation in Huntington's disease Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington's disease model.N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses.Microglial Activation in the Pathogenesis of Huntington's Disease.Targets for future clinical trials in Huntington's disease: what's in the pipeline?Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington's disease A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.Probing the stress and depression circuits with a disease gene.Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease.A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease Preclinical models: needed in translation? A Pro/Con debate.Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury.Allele-selective suppression of mutant genes in polyglutamine diseases.Viral vectors for therapy of neurologic diseases.Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.Something wicked this way comes: huntingtin.Therapies targeting DNA and RNA in Huntington's disease.Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice.The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications.Cdk5 Contributes to Huntington's Disease Learning and Memory Deficits via Modulation of Brain Region-Specific Substrates.Meta-analytic evaluation of the association between head injury and risk of amyotrophic lateral sclerosis.Molecular insights into cortico-striatal miscommunications in Huntington's disease.

P2860

Q26799722-D97D34F2-7209-4986-A1D5-266E0CD6FFA3 Q26828403-856DE564-1FC4-4C34-8F2B-A50A3E6B8B9D Q26849677-739D09F1-4C2A-4FD7-AFBD-643889A529B4 Q27301298-800EB015-B23F-4EFF-BE8A-49FB9E433104 Q27306025-E8C089D5-1646-44BE-8A8D-7376F62C7467 Q27346849-9682B7EA-4E39-462D-83C1-16919910A88D Q30408636-0DCD0CEF-5569-48EF-A3CD-FBACFF47BC0F Q30827953-9F811531-1A87-42CA-B542-5D1BDB673281 Q33809556-20BA7D62-9518-4133-98D8-1CF56A89A958 Q34435001-56710C38-C443-4959-8D4B-C79C9137CCD8 Q35164101-6F54A1C0-5DB9-40FB-97D7-178AB380501C Q35214858-D6B28E78-0A5B-473C-88E1-82D8D0AC52E9 Q35560350-904D068A-F310-4C92-819F-B99945E11492 Q36059819-BEA698C9-6A37-4BDF-8AE5-18088320E129 Q36206024-3E27C00A-7F39-48C1-B789-6365E74B4C98 Q36331582-BDEBCE8F-724F-4DE2-8A41-83487E44394E Q36431970-E93714C8-0841-4887-ADB3-64CB80B4AABB Q36461072-9CD4D328-3BF3-41B0-AD0F-337D714920EF Q36951265-CB90CC38-A6A5-4B6E-A222-2BD51C09191F Q37051728-06F331D9-BE5C-41CD-A8BB-012C7A4FD692 Q37088539-AAE62F68-113B-48DE-9A92-D6BF60322F86 Q37281403-55702B22-006E-4466-9204-6CC38F1EBF4C Q38248688-AF38EA63-B82E-45B0-9FB0-93A08EA4021E Q38263989-74324003-ACE4-46C6-97A3-899828680498 Q38547027-6C47B98F-7588-431B-ADF8-2B3DC126C56E Q38746238-84CA7DAB-F5D7-4EA0-86CE-A07EBE85660C Q38925490-CF1933B6-04C5-49CD-99D8-99A73B60AA35 Q38928777-4EB06DAD-972F-409F-B4BE-5FB7463F4AEE Q39041217-2626B539-E63F-4515-B577-23F6885FB679 Q39165036-7137C633-E5B8-4473-9E25-84104D759D71 Q40102175-AFDADFEE-BDF9-4A10-BC10-6BC29A139CEB Q40558924-6842A400-E287-450B-B0CB-6BCCD2B7202B Q45138428-50A4E2E6-0A83-4B3F-893F-C3BAF9EBCD75 Q45300759-09F2B5A3-0CDC-41EB-AD0E-1411DF3135D7 Q45304275-F3BB791D-0B7D-42A3-A1F6-05C69F3F9FDC Q46306829-ADC3412E-4CA3-4064-B296-BBD8CFE386E4 Q47102449-77973378-C664-437D-BDC9-794F554883D6 Q47890221-9C44A81E-3087-47F9-BAE9-4E921A57A07B Q48110461-D1705906-198A-48F2-B0B9-874CBC91BCFE Q50069504-953E1F4C-230F-46B1-96DD-4AB1188FE469

P2860

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

http://www.wikidata.org/entity/Q30581321

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Neuronal targets for reducing ...... model of Huntington's disease

@ast

Neuronal targets for reducing ...... model of Huntington's disease

@en

type

label

Neuronal targets for reducing ...... model of Huntington's disease

@ast

Neuronal targets for reducing ...... model of Huntington's disease

@en

prefLabel

Neuronal targets for reducing ...... model of Huntington's disease

@ast

Neuronal targets for reducing ...... model of Huntington's disease

@en

P1433

Q30581321-51C898A3-64B6-4773-B065-D296B1DC9459

P1476

Q30581321-63EA109A-52C1-45BB-93EC-28B0097749E4

P2093

Q30581321-157E4D5F-3A6D-4EC5-BB89-7745FB4FF058

Q30581321-1EDD52D2-1E89-4C94-A24B-FD6759779F3D

Q30581321-2EFB3983-AC4E-45DA-848B-4E82D8F3F50E

Q30581321-366723C3-B6D6-433C-AD6B-8D01CFEC02CA

Q30581321-47202F29-583A-42A2-B45B-668F39BB5DBE

Q30581321-5A4790CF-0E27-45DE-B2EC-752B7DF003BE

Q30581321-6146E560-40DB-4256-8ECB-A9486F9B4EE7

Q30581321-A350C2FB-6A5A-42AF-BBC3-8F8BF9F54A66

Q30581321-B9AC39F8-27C9-4610-A9A7-525DA1F3C31C

Q30581321-D70AB72A-FAA1-4EAE-B5AE-697FC114E78E

P2860

Q30581321-061AFB06-BED4-48AF-A394-8B16C083A25F

Q30581321-07FB6A8C-D29A-42AD-9091-1580EF17E6A6

Q30581321-0B241109-5A40-4326-8017-A2B57460667A

Q30581321-1909CD2A-83DF-49C5-A560-1EAB4D3C1BF9

Q30581321-1C24C706-9EB5-473B-80AC-FB2CCA4BF5F6

Q30581321-206CB737-7AEC-4A3B-9472-C93497867400

Q30581321-2DCCF9C7-27F2-4552-B085-A725F50A4D50

Q30581321-30E81B47-43E0-44E0-8A0F-EAC92F61794C

Q30581321-3819B265-7794-47B6-B479-A5BC5F453D81

Q30581321-3D0D1934-81E7-4E4A-9E87-FDA2440156DE

P2888

Q30581321-6CD83D10-7001-4F9C-8E14-9A3B1AC8F383

P304

Q30581321-F1433526-7E79-4592-B701-9D63C7E6E293

P31

Q30581321-2F17A0E7-FF9D-433E-B55C-8FD95B0C2282

P356

Q30581321-05842AF9-BC2B-4208-AB32-636E2E7FA60D

P407

Q30581321-F40321D9-D47C-4A77-9AF4-2989AEF71C0E

P433

Q30581321-FA797933-A8EA-4B2B-90AC-14F815CA3092

P478

Q30581321-EB9F8663-BCE1-432C-8E49-0BF3835EBE98

P50

Q30581321-D5CA4C47-5138-4C4D-A202-9730E7204B66

P577

Q30581321-9B775DC7-0D1B-426F-A339-49728A92BCE5

P5875

Q30581321-DDCACBA0-99E8-479A-B542-B7D284A1AB0B

P698

Q30581321-31E8D153-6166-447A-99F8-4CBA3B36DF5D

P921

Q30581321-0159D09E-30C4-4EBC-A163-5EBF99E6DCE4

P932

Q30581321-9A486AF5-32F6-4E91-9E91-B7788B976B70

P356

P1433

Nature Medicine

P1476

Neuronal targets for reducing ...... model of Huntington's disease

@en

P2093

Carlos Cepeda

http://www.w3.org/2001/XMLSchema#string

Dyna Shirasaki

http://www.w3.org/2001/XMLSchema#string

Erin Greiner

http://www.w3.org/2001/XMLSchema#string

Hongwei Dong

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Cantle

http://www.w3.org/2001/XMLSchema#string

Michael S Levine

http://www.w3.org/2001/XMLSchema#string

Michelle Gray

http://www.w3.org/2001/XMLSchema#string

Nan Wang

http://www.w3.org/2001/XMLSchema#string

Sandra M Holley

http://www.w3.org/2001/XMLSchema#string

X William Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice

Huntingtin interacting proteins are genetic modifiers of neurodegeneration

Oligonucleotide therapeutic approaches for Huntington disease

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Generalized lacZ expression with the ROSA26 Cre reporter strain

The postsynaptic density at glutamatergic synapses

Huntington's disease

Competitive binding of alpha-actinin and calmodulin to the NMDA receptor

Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum

Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex

P2888

P304

536-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3514

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262015029

http://www.w3.org/2001/XMLSchema#string

P698

24784230

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

4067603

http://www.w3.org/2001/XMLSchema#string